Premium
TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3
Author(s) -
Shaughnessy John D.,
Zhou Yiming,
Haessler Jeff,
Van Rhee Frits,
Anaissie Elias,
Nair Bijay,
Waheed Sarah,
Alsayed Yazan,
Epstein Joshua,
Crowley John,
Barlogie Bart
Publication year - 2009
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2009.07864.x
Subject(s) - multiple myeloma , medicine , bortezomib , oncology , adverse effect , chromosomal translocation , hematology , biology , gene , genetics
Summary Contrary to Total Therapy (TT) 2 for multiple myeloma patients, FGFR3 − translocation bore no adverse effects on outcome in TT3 with added bortezomib. Del TP53 , another poor‐risk feature in TT2 and present in 10% of 441 patients treated, was examined for its prognostic consequences in TT3. Not affecting rate or duration of complete response, TP53 haplo‐insufficiency also did not compromise, in the 83% with genomically defined low‐risk myeloma, survival or event‐free survival. FGFR3 + and FGFR3 − molecular subgroups fared worse in the presence of del TP53 when applying TT2 but not TT3. Thus, the prognostic implications of del TP53 were protocol‐, genome‐defined risk‐ and molecular subgroup‐dependent.